{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:37:49Z","timestamp":1784068669983,"version":"3.55.0"},"reference-count":61,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Monoclonal Antibodies in Immunodiagnosis &amp; Immunotherapy"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>\n                    Erythropoietin-producing hepatocellular receptor A1 (EphA1) is one of the Eph receptor family members, the largest group of receptor tyrosine kinases. EphA1 is expressed in various tissues and regulates cellular homeostasis by interacting with its membrane-bound ephrin ligands and other receptors. EphA1 critically correlates with the pathogenesis in several disorders, including Alzheimer\u2019s disease and cancers. Therefore, establishing sensitive monoclonal antibodies (mAbs) for EphA1 has been desired for basic research, diagnosis, and treatment. In this study, a novel specific and sensitive anti-human EphA1 mAb, clone Ea\n                    <jats:sub>1<\/jats:sub>\n                    Mab-30 (mouse IgG\n                    <jats:sub>1<\/jats:sub>\n                    , kappa), was established by the Cell-Based Immunization and Screening (CBIS) method. Ea\n                    <jats:sub>1<\/jats:sub>\n                    Mab-30 demonstrated reactivity with an EphA1-overexpressed Chinese hamster ovary-K1 cell line (CHO\/EphA1), an endogenously EphA1-expressing bladder carcinoma cell line (5637), and a colorectal adenocarcinoma cell line (Caco-2) in flow cytometry. Crossreactivities of Ea\n                    <jats:sub>1<\/jats:sub>\n                    Mab-30 with other Eph receptors were not observed. Furthermore, the values of apparent binding affinity for CHO\/EphA1 and 5637 were determined to be 8.9 \u00d7 10\n                    <jats:sup>\u22129<\/jats:sup>\n                    M and 1.7 \u00d7 10\n                    <jats:sup>\u22129<\/jats:sup>\n                    M, respectively. Furthermore, Ea\n                    <jats:sub>1<\/jats:sub>\n                    Mab-30 detected EphA1 protein in CHO\/EphA1 and 5637 lysates using Western blot analysis. Ea\n                    <jats:sub>1<\/jats:sub>\n                    Mab-30 also clearly stained EphA1 of formalin-fixed paraffin-embedded CHO\/EphA1 using immunohistochemistry. Ea\n                    <jats:sub>1<\/jats:sub>\n                    Mab-30, established by CBIS method, could help analyze the EphA1-contributed cellular functions and have potential applications in pathological diagnosis and treatment with specificity and high affinity for EphA1-expressing cells.\n                  <\/jats:p>","DOI":"10.1089\/mab.2025.0006","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T08:50:57Z","timestamp":1750841457000},"page":"41-52","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of a Novel Anti-human EphA1 Monoclonal Antibody, Ea\n                    <sub>1<\/sub>\n                    Mab-30, for Multiple Applications"],"prefix":"10.1177","volume":"44","author":[{"given":"Tomohiro","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Miyagi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Miyagi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honoka","family":"Taruta","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Miyagi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Saga","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Miyagi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanjie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Miyagi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Miyagi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4158-9208","authenticated-orcid":false,"given":"Mika K.","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Miyagi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5385-8201","authenticated-orcid":false,"given":"Yukinari","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Miyagi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81436-1"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08995"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2825356"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/08977190109029118"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.036467"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2005.06.052"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.conb.2009.04.009"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0707210104"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/147323001103900220"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/dvg.20434"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2802"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-019-01420-x"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.801"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2014.05.006"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000369101"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1072994"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.108099"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.803"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170468"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050976"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0463.2012.02941.x"},{"issue":"6","key":"e_1_3_4_23_2","first-page":"1577","article-title":"Expression of EphA1 in gastric carcinomas is associated with metastasis and survival","volume":"24","author":"Wang J","year":"2010","unstructured":"Wang J, , Dong Y, , Wang X, et al. Expression of EphA1 in gastric carcinomas is associated with metastasis and survival. Oncol Rep, 2010; 24(6):1577\u20131584; doi: 10.3892\/or_00001020","journal-title":"Oncol Rep"},{"key":"e_1_3_4_24_2","first-page":"e923409","article-title":"Association Between EphA1 and Tumor Microenvironment in Gastric Carcinoma and its Clinical Significance","volume":"26","author":"Wang YC","year":"2020","unstructured":"Wang YC, , Dai Y, , Xu GL, et al. Association Between EphA1 and Tumor Microenvironment in Gastric Carcinoma and its Clinical Significance. Med Sci Monit, 2020; 26:e923409; doi: 10.12659\/msm.923409","journal-title":"Med Sci Monit"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.12.5958"},{"issue":"9","key":"e_1_3_4_26_2","first-page":"1854","article-title":"Increased expression of EphA1 protein in prostate cancers correlates with high Gleason score","volume":"6","author":"Peng L","year":"2013","unstructured":"Peng L, , Wang H, , Dong Y, et al. Increased expression of EphA1 protein in prostate cancers correlates with high Gleason score. Int J Clin Exp Pathol, 2013; 6(9):1854\u20131860.","journal-title":"Int J Clin Exp Pathol"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-21-1367"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.112009"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.180"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2008.188"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604970"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800660"},{"issue":"4","key":"e_1_3_4_33_2","first-page":"5409","article-title":"Decreased Eph receptor-A1 expression is related to grade in ovarian serous carcinoma","volume":"17","author":"Jin Y","year":"2018","unstructured":"Jin Y, , Zou Y, , Wan L, et al. Decreased Eph receptor-A1 expression is related to grade in ovarian serous carcinoma. Mol Med Rep, 2018; 17(4):5409\u20135415; doi: 10.3892\/mmr.2018.8528","journal-title":"Mol Med Rep"},{"issue":"10","key":"e_1_3_4_34_2","first-page":"225","article-title":"Ephrin receptors (Eph): EphA1, EphA5, and EphA7 expression in uveal melanoma-associations with clinical parameters and patient survival","volume":"10","author":"Gajdzis M","year":"2020","unstructured":"Gajdzis M, , Theocharis S, , Gajdzis P, et al. Ephrin receptors (Eph): EphA1, EphA5, and EphA7 expression in uveal melanoma-associations with clinical parameters and patient survival. Life (Basel), 2020; 10(10):225; doi: 10.3390\/life10100225","journal-title":"Life (Basel)"},{"key":"e_1_3_4_35_2","article-title":"An Anti-Human EphA2 Monoclonal Antibody Ea2Mab-7 Shows High Sensitivity for Flow Cytometry, Western Blot, and Immunohistochemical Analyses","author":"Satofuka HSH","year":"2024","unstructured":"Satofuka HSH, , Tanaka T, , Li G, et al. An Anti-Human EphA2 Monoclonal Antibody Ea2Mab-7 Shows High Sensitivity for Flow Cytometry, Western Blot, and Immunohistochemical Analyses. Preprint, 2024; doi: 10.20944\/preprints202410.0572.v1","journal-title":"Preprint"},{"issue":"0","key":"e_1_3_4_36_2","first-page":"5728","article-title":"Establishment of a highly sensitive and specific anti-EphB2 monoclonal antibody (Eb2Mab-12) for flow cytometry","volume":"0","author":"Ubukata R","year":"2025","unstructured":"Ubukata R, , Suzuki H, , Hirose M, et al. Establishment of a highly sensitive and specific anti-EphB2 monoclonal antibody (Eb2Mab-12) for flow cytometry. MI, 2025; 0(0):5728; doi: 10.36922\/mi.5728","journal-title":"MI"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2023.0015"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2025.101960"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2016.0039"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2014.01.009"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10014-015-0222-8"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19788-y"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25147"},{"issue":"6","key":"e_1_3_4_44_2","first-page":"6821","article-title":"Expression of the EphA1 protein is associated with Fuhrman nuclear grade in clear cell renal cell carcinomas","volume":"8","author":"Wang X","year":"2015","unstructured":"Wang X, , Liu Y, , Cao G, et al. Expression of the EphA1 protein is associated with Fuhrman nuclear grade in clear cell renal cell carcinomas. Int J Clin Exp Pathol, 2015; 8(6):6821\u20136827.","journal-title":"Int J Clin Exp Pathol"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2024.02.007"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells13221833"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5575704"},{"issue":"5","key":"e_1_3_4_48_2","first-page":"1220","article-title":"Overexpressed gene signature of EPH receptor A\/B family in cancer patients-comprehensive analyses from the public high-throughput database","volume":"13","author":"Phan NN","year":"2020","unstructured":"Phan NN, , Liu S, , Wang CY, et al. Overexpressed gene signature of EPH receptor A\/B family in cancer patients-comprehensive analyses from the public high-throughput database. Int J Clin Exp Pathol, 2020; 13(5):1220\u20131242.","journal-title":"Int J Clin Exp Pathol"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00634-x"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon.09.146"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph13050088"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.56"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.conb.2019.11.024"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-021-03986-5"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.439"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13603"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105752"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168593"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1740925X09990287"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-020-02122-x"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2024.100700"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep05924"}],"container-title":["Monoclonal Antibodies in Immunodiagnosis &amp; Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mab.2025.0006","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mab.2025.0006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mab.2025.0006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:22:40Z","timestamp":1777666960000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mab.2025.0006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1089\/mab.2025.0006"],"URL":"https:\/\/doi.org\/10.1089\/mab.2025.0006","relation":{},"ISSN":["2167-9436","2167-9436"],"issn-type":[{"value":"2167-9436","type":"print"},{"value":"2167-9436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}